| Clinical data | |
|---|---|
| Trade names | Etilamide |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | X |
| Legal status | ℞-only |
| Routes | implant, intranasal |
| Pharmacokinetic data | |
| Half-life | 72 to 80 minutes |
| Excretion | Renal |
| Identifiers | |
| CAS number | 57982-77-1 |
| ATC code | L02AE01 QH01CA90 |
| PubChem | CID 50225 |
| DrugBank | HMDB03170 |
| ChemSpider | 45545 |
| UNII | PXW8U3YXDV |
| Synonyms | D-Ser(Tbu)6EA10LHRH |
| Chemical data | |
| Formula | C62H90N16O15 |
| Mol. mass | 1299.48 g/mol |
|
|
| (what is this?) (verify) |
|
Buserelin is a Gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
It is normally delivered via a nasal spray but is also available as an injection.
Buserelin acetate is marketed by Sanofi-Aventis under the brand name Suprefact and a generic form of Buserelin is now produced by CinnaGen under the brand name CinnaFact.
Buserelin is also marketed under the brand name Metrelef. Metrelef is approved to treat patients with endometriosis by suppression of ovarian hormone production. In ovulation induction Metrelef is used as a pituitary blockade as an adjunct to gonadotrophin administration.
|
|||||||||||||||||||||